Disease recurrence correlates with treatment resistance, creating a major need to resensitize tumors to treatment.
Erik W. J. Mollen, Erik W. J. Mollen, Erik W. J. Mollen, Jonathan Ient, Vivianne C.G. Tjan-Heijnen, Vivianne C. G. Tjan-Heijnen, Liesbeth J. Boersma, Liesbeth J. Boersma,Lucio Miele, Lucio Miele, Marjolein L. Smidt, Marjolein L. Smidt, Marc A. G. G. Vooijs,Marc A. G. G. Vooijs 2018, 'Moving Breast Cancer Therapy up a Notch', Frontiers in Oncologyhttps://www.frontiersin.org/article/10.3389/fonc.2018.00518/full. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)
The patient population struggling with therapeutic resistance specifically requires novel treatment options to resensitize these tumor cells to therapy.
Terra Arnason, Troy Harkness 2015, 'Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroadsof TFPI1, ABC Transporters, and HIF1', Cancershttp://www.mdpi.com/2072-6694/7/4/0877. Retrieved from DOAJ CC BY 4.0 (https://creativecommons.org/licenses/by-sa/4.0/legalcode)